510(k) · Cleared
ClearedCefaly Dual
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Cefaly Technology · PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine
Cleared on Nov 28, 2017 as substantially equivalent to K171446 (Cefaly Technology, 2017) and 1 other predicate after a 62-day review. Its family tree reaches back 3 generations to 2014. 10 later devices descend from it.
- Decided
- Nov 28, 2017
- Review
- 62 days
- Class
- Class II
- Product code
- PCC
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 3 generations to DEN120019 (2014). 10 later devices descend from it, 3 citing it directly.
- Root · 3 generations backDEN120019 CefalyStx-Med Sprl · 2014
- 2 generations backK160237 CefalyCefaly Technology · 2016
- 1 generation backK171446 Cefaly AcuteCefaly Technology · 2017
- This deviceK173006 Cefaly DualCefaly Technology · 2017
- Descendant · cites it directly · 7 of its ownK201895 Cefaly DualCefaly Technology · 2020
- Descendant · cites it directly · 2 of its ownK212071 Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID…Cefaly Technology · 2022
- Descendant · 2 generations on · 1 of its ownK234029 CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024
- Descendant · cites it directly · 1 of its ownK211380 ElexirNu Eyne Co., Ltd. · 2021
- Descendant · 3 generations on · 0 of its ownK254216 Enso for MigraineHinge Health, Inc. · 2026
Showing 5 of 10 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 10 · See all- K201895Cefaly DualCefaly Technology · 2020 · cites it directly7descendants
- K212071Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual…Cefaly Technology · 2022 · cites it directly2descendants
- K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024 · 2 generations on1descendant
- K211380ElexirNu Eyne Co., Ltd. · 2021 · cites it directly1descendant
- K254216Enso for MigraineHinge Health, Inc. · 2026 · 3 generations on0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | DEN120019 | Cefaly | Stx-Med Sprl | 2014 | — |
| −2 | K160237 | Cefaly | Cefaly Technology | 2016 | — |
| −1 | K171446 | Cefaly Acute | Cefaly Technology | 2017 | — |
| 0 (this device) | K173006 | Cefaly Dual | Cefaly Technology | 2017 | — |
| +1 | K201895 | Cefaly Dual | Cefaly Technology | 2020 | — |
| +1 | K212071 | Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx… | Cefaly Technology | 2022 | — |
| +2 | K234029 | CEFALY Connected - OTC, CEFALY Connected - Rx | Cefaly Technology | 2024 | — |
| +1 | K211380 | Elexir | Nu Eyne Co., Ltd. | 2021 | — |
| +3 | K254216 | Enso for Migraine | Hinge Health, Inc. | 2026 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2020 | 1 | 0 |
| 2021 | 2 | 0 |
| 2022 | 1 | 0 |
| 2024 | 5 | 0 |
| 2026 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in PCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new PCC device
- #1 K201895 Cefaly Dualscore 16.0 · 4 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K171446 | Cefaly AcuteSummary page 4…valency Substantial Equivalency is claimed against the following legally marketed devices: • Cefaly® Acute (510(k) number K171446) • Cefaly® (510(k) number K160237) In particular, while the Cefaly® Acute h… | 2017 |
| * | K160237 | CefalySummary page 4…he following legally marketed devices: • Cefaly® Acute (510(k) number K171446) • Cefaly® (510(k) number K160237) In particular, while the Cefaly® Acute has one stimulation program indicated for the acute tr… | 2016 |
What descends from it? (10)
3 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 3 years and passes through 2 companies; a new generation was cleared every 1.5 years on median.
- None of the 3 ancestors has a recall.
- Of its descendants, K201895 (Cefaly Technology, 2020) has gone furthest, with 7 descendants of its own.
- 1 other device also cites its predicate K171446.
How does its category compare?
All PCC devicesPCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.
FDA decisions per year · PCC
5in 2024
2026 to Oct 25, outlined.
Median 510(k) review, days · PCC
211in 2024
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · PCC
No recall names PCC since 2007.
Adverse event reports per year · PCC
2in 2025
MAUDE reports naming product code PCC, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 2 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 2 |
| 2017 | 2 | — | 0 | 2 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 1 | — | 0 | 2 |
| 2020 | 1 | — | 0 | 1 |
| 2021 | 4 | 88 | 0 | 7 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 2 |
| 2024 | 5 | 211 | 0 | 6 |
| 2025 | 0 | — | 0 | 2 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
The Cefaly® Dual is indicated for:
- The acute treatment of migraine with or without aura in patients 18 years of age or older.
- The prophylactic treatment of episodic migraine in patients 18 years of age or older.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K173006 · printed Nov 6, 2026
Cite this page
510(k) Report. “K173006: Cefaly Dual.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K173006
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026